MR Enterography Predictors of Disease Relapse After Stopping Biologic Therapy in Crohn's Disease (METEOR).

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study aims to investigate if MR Enterography (MRE) improves the ability to predict which Crohn's disease patients will relapse quickly (disease comes back) after stopping biologic medication. MRE is a safe MRI scan of the bowel, widely used in Crohn's disease patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: f
View:

• Luminal small bowel or colonic Crohn's disease in clinical remission

• 16 years or older

• MRE as part of routine care performed within three months prior, or one month after the decision to stop biologic therapy Anti-TNF (Adalimumab, infliximab, Certolizumab) IL-23 or IL-12 antagonists (Ustekinumab) Anti-integrin biologics (Natalizumab, Vedolizumab)

• Biologic therapy stopped due to clinical remission only

⁃ Definition of clinical remission: There is no agreed consensus on how clinical remission is defined and practice differs between hospitals and patients. To mirror current clinical practice, no strict definition of clinical remission will therefore be used. Detailed clinical parameters the time of stopping biologic agents will be collected.

Locations
Other Locations
United Kingdom
University College London Hospital
RECRUITING
London
Contact Information
Primary
Maira Hameed
maira.hameed@ucl.ac.uk
020 7679 9274
Backup
Elizabeth Isaac
e.isaac@nhs.net
02034474415
Time Frame
Start Date: 2024-02-27
Estimated Completion Date: 2027-02
Participants
Target number of participants: 150
Treatments
Crohn's Disease patients stopping biologic therapy
Crohn's Disease patients stopping biologic therapy and undergoing MR Enterography 3 months before or 1 month after this decision as part of standard clinical care.
Related Therapeutic Areas
Sponsors
Leads: University College, London
Collaborators: British Society of Gastrointestinal and Abdominal Radiology (BSGAR)

This content was sourced from clinicaltrials.gov